Back to results
US 12,558,413 B2Granted
IL-10 inhibition for vaccines and immunotherapy
AssigneeThe Regents of the University of California
InventorDennis Hartigan-O'Connor
Life of this patent
Estimating the term…
Abstract
Provided herein are methods for inducing an immune response against an antigen in a subject. In some embodiments, the methods comprise administering a therapeutically effective amount of a vaccine and an interleukin 10 (IL-10) inhibitor to the subject. In some embodiments, the vaccine is an IL-10-deficient vaccine.
Claims18
A method for inducing an immune response against an antigen in a subject, the method comprising administering to the subject an interleukin 10 (IL-10)-deficient vaccine and a therapeutically effective amount of an IL-10 inhibitor,
- wherein the IL-10-deficient vaccine comprises a recombinant polynucleotide comprising a cytomegalovirus (CMV) genome, or a portion thereof, and a nucleic acid sequence encoding the antigen, wherein:
- (i) a portion of the CMV genome encodes a protein that has interleukin-10 (CMV IL-10)-like activity;
- and
- (ii) the portion of the CMV genome in (i) comprises one or more immunomodulatory mutations, and
- wherein the IL-10 inhibitor comprises:
- (a) a truncated IL-10 receptor protein comprising the amino acid sequence set forth in any one of SEQ ID NOS:
- 5-6 but lacking the portion of the IL-10 receptor protein necessary for intracellular signaling;
- (b) a truncation of a protein having IL-10-like activity, wherein the truncation consists of the amino acid sequence set forth in SEQ ID NO:7:
- (c) a dominant-negative STAT3 protein comprising the amino acid sequence set forth in any one of SEQ ID NOS:
- 8-10;
- or
- (d) a nucleic acid sequence encoding the IL-10 inhibitor.
9 more elements
Dependencies are inferred from the claim text.